Checkpoint Inhibitor Immunotherapy Delays Colorectal Cancer Progression

In June 2020, the FDA approved the immunotherapy drug Keytruda as the first-line (initial) treatment instead of chemotherapy for patients with inoperable or metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer.  These features are hallmarks of most Lynch Syndrome tumors.  

Learn More:
https://www.curetoday.com/view/fda-approves-keytruda-as-initial-treatment-for-advanced-colorectal-cancer-with-dna-repair-defects